BRPI0517564A - métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica - Google Patents

métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica

Info

Publication number
BRPI0517564A
BRPI0517564A BRPI0517564-0A BRPI0517564A BRPI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A BR PI0517564 A BRPI0517564 A BR PI0517564A
Authority
BR
Brazil
Prior art keywords
adenoma
adenocarcinoma
cell
intestinal
methods
Prior art date
Application number
BRPI0517564-0A
Other languages
English (en)
Inventor
Johannes Carolus Clevers
Gijn Maria Elisabeth Van
Es Johannes Hendrikus Van
Original Assignee
Hubrecht Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubrecht Lab filed Critical Hubrecht Lab
Publication of BRPI0517564A publication Critical patent/BRPI0517564A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS PARA MODIFICAR O DESTINO DE UMA CéLULA DE ADENOMA E/OU ADENOCARCINOMA, PARA INDUZIR A FORMAçãO DE UMA CéLULA PóS-MITóTICA A PARTIR DE UM CéLULA DE ADENOMA E/OU ADENOCARCINOMA E PARA, PELO MENOS EM PARTE, DIMINUIR UM ADENOMA E/OU ADENOCARCINOMA INTESTINAL PRESENTE EM UM ANIMAL, USO DE UM INIBIDOR DO TRAJETO DE NOTCH, E, COMPOSIçãO FARMACêUTICA. A invenção refere-se ao campo da bioquímica e medicina. Mais especificamente, a invenção refere-se a métodos e produtos farmacêuticos para o tratamento de um neoplasia intestinal. A invenção descreve a surpreendente descoberta de que inibidores de ativação de trajeto de Notch (por exemplo inibidores de g-secretase) são extremamente úteis no tratamento de adenoma e/ou adenocarcinoma intestinal.
BRPI0517564-0A 2004-11-10 2005-11-10 métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica BRPI0517564A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078090 2004-11-10
EP05075806 2005-04-06
PCT/NL2005/000788 WO2006052128A1 (en) 2004-11-10 2005-11-10 Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation

Publications (1)

Publication Number Publication Date
BRPI0517564A true BRPI0517564A (pt) 2008-10-14

Family

ID=36336759

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517564-0A BRPI0517564A (pt) 2004-11-10 2005-11-10 métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica

Country Status (11)

Country Link
US (2) US20070265246A1 (pt)
EP (1) EP1824503A1 (pt)
JP (1) JP2008519829A (pt)
AU (1) AU2005302846A1 (pt)
BR (1) BRPI0517564A (pt)
CA (1) CA2586781A1 (pt)
IL (1) IL183031A0 (pt)
NO (1) NO20072951L (pt)
NZ (1) NZ555216A (pt)
RU (1) RU2392961C2 (pt)
WO (1) WO2006052128A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
JP2008519829A (ja) * 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
EP1795198A1 (en) * 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008100563A2 (en) * 2007-02-14 2008-08-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012080926A2 (en) * 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
CN102266587B (zh) * 2011-07-20 2013-12-04 山东省眼科研究所 一种含杯状细胞的重组眼结膜上皮膜片的制备方法
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
EP2606884A1 (en) * 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
BR112014020233A2 (pt) * 2012-02-28 2017-07-04 Irm Llc seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
RU2712302C1 (ru) * 2019-07-24 2020-01-28 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения операбельной аденокарциномы двенадцатиперстной кишки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2134549C1 (ru) * 1996-04-17 1999-08-20 Валерий Леонтьевич Валецкий Способ лечения рака желудка
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1410018A1 (en) * 2001-07-25 2004-04-21 Lorantis Limited Method for detecting modultators of notch signalling
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
CA2516259A1 (en) * 2003-02-18 2004-09-02 Roskamp Research, Llc Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
JP2008519829A (ja) * 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
AU2005316217A1 (en) * 2004-12-17 2006-06-22 Memorial Sloan Kettering Cancer Center Regulation of metalloprotease cleavage of cell surface proteins
EP1795198A1 (en) * 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus

Also Published As

Publication number Publication date
RU2007121737A (ru) 2008-12-20
NO20072951L (no) 2007-08-09
US20070265246A1 (en) 2007-11-15
CA2586781A1 (en) 2006-05-18
EP1824503A1 (en) 2007-08-29
RU2392961C2 (ru) 2010-06-27
NZ555216A (en) 2010-05-28
WO2006052128A1 (en) 2006-05-18
US20100292165A1 (en) 2010-11-18
JP2008519829A (ja) 2008-06-12
AU2005302846A1 (en) 2006-05-18
IL183031A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20072951L (no) Behandling av et intestinalt adenom og/eller adenokarsinom ved hemming av Notch-reaksjonsveiaktivering
CY1111551T1 (el) Φαρμακευτικος συνδυασμος που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και nsaid
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
SE0301700D0 (sv) Novel compounds
EA201001255A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применения
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EP2365750A4 (en) BENZOXAZOLE KINASE INHIBITORS AND METHOD FOR THEIR USE
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
CY1113141T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CL2008003486A1 (es) 6-oxo-1,6-dihidropiridazinas; sus usos para tratar un trastorno hiperproliferativo; la composición farmacéutica que las contiene; y sus procesos de preparación (div. sol. 1168-06).
NO20090295L (no) Substituerte heteroarylderivater
BRPI0409068A (pt) composições farmacêuticas para inibidores de protease viral de hepatite c.
BRPI0510142A (pt) compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
NO20084190L (no) Anvendelse av VX-702 til behandling av revmatoid artritt
DK1589834T3 (da) Enteral komposition til forebyggelse og/eller behandling af sepsis
BRPI0517132B8 (pt) uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]